Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697489 | 0.85 | MAPT (0.68) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL2975743 | 0.85 | MAPT (0.68) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL29561542 | 0.85 | MAPT (0.68) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL24141032 | 0.83 | MAPT (0.84) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL13549872 | 0.83 | MAPT (0.70) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL13202441 | 0.83 | MAPT (0.70) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL11791073 | 0.82 | RXFP1 (0.79) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL23447711 | 0.82 | MAPT (0.82) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL4286068 | 0.82 | MAPT (0.94) | MAPTRXFP1KCNK3P2RX1LMNA | |
| SCHEMBL17936028 | 0.81 | MAPT (0.64) | MAPTRXFP1KCNK3P2RX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2121692-B1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2121692-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008079965-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | MAPT 4133/4885RXFP1 4578/4885KCNK3 1339/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | MAPT 4015/4885RXFP1 4079/4885KCNK3 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.